[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
In 30 patients with prostatic carcinoma a higher of t-PA, a low of PAI-1, alpha 2-antiplasmin and plasminogen activity with increased fibrin degradation products (FDP) level and a short euglobulin lysis time (ELT) were observed. Following surgery a further increased of fibrinolytic activity occurred. The activity of t-PA and PAI-1 were higher than before operation. Apart from that we observed a decreased of plasminogen and alpha 2-AP with further increased level of FDP. On 5-th day the values of examined parameters were similar as before the operation.
Iwan-Zietek
I
I
Katedry i Zakładu Patofizjologii, Katedry i Kliniki Urologii Akademii Medycznej, Bydgoszczy.
Zietek
Z
Z
Kotschy
M
M
Rość
D
D
Tyloch
F
F
D000368:Aged; D000369:Aged, 80 and over; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D010960:Plasminogen Activators / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000601:surgery; D015842:Serine Proteinase Inhibitors / Q000097:blood*; D010959:Tissue Plasminogen Activator / Q000097:blood*; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D000979:alpha-2-Antiplasmin; D010958:Plasminogen; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin
Tkankowy aktywator plazminogenu i jego inhibitor we krwi chorych operowanych z powodu raka gruczołu krokowego.